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Abstract
Background: The aim of this study is to analyse the prevalence of transmitted drug resistance, TDR, and the impact of TDR
on treatment success in the German HIV-1 Seroconverter Cohort.
Methods: Genotypic resistance analysis was performed in treatment-naı ¨ve study patients whose sample was available
1,312/1,564 (83.9% October 2008). A genotypic resistance result was obtained for 1,276/1,312 (97.3%). The resistance
associated mutations were identified according to the surveillance drug resistance mutations list recommended for drug-
naı ¨ve patients. Treatment success was determined as viral suppression below 500 copies/ml.
Results: Prevalence of TDR was stable at a high level between 1996 and 2007 in the German HIV-1 Seroconverter Cohort
(N=158/1,276; 12.4%; CIwilson 10.7–14.3; p for trend=0.25). NRTI resistance was predominant (7.5%) but decreased signifi-
cantly over time (CIWilson: 6.2–9.1, p for trend=0.02). NNRTI resistance tended to increase over time (NNRTI: 3.5%; CIWilson: 2.6–
4.6; p for trend =0.07), whereas PI resistance remained stable (PI: 3.0%; CIWilson: 2.1–4.0; p for trend =0.24). Resistance to all
drug classes was frequently caused by singleton resistance mutations (NRTI 55.6%, PI 68.4%, NNRTI 99.1%). The majority of
NRTI-resistant strains (79.8%) carried resistance-associated mutations selected by the thymidine analogues zidovudine and
stavudine. Preferably 2NRTI/1PIr combinations were prescribed as first line regimen in patients with resistant HIV as well as
in patients with susceptible strains (susceptible 45.3%; 173/382 vs. resistant 65.5%; 40/61). The majority of patients in both
groups were treated successfully within the first year after ART-initiation (susceptible: 89.9%; 62/69; resistant: 7/9; 77.8%).
Conclusion: Overall prevalence of TDR remained stable at a high level but trends of resistance against drug classes differed
over time. The significant decrease of NRTI-resistance in patients newly infected with HIV might be related to the
introduction of novel antiretroviral drugs and a wider use of genotypic resistance analysis prior to treatment initiation.
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Introduction
Testing for HIV resistance to antiretroviral drugs in plasma is a
rational supplement to guide clinicians in their therapeutic choice
for patients receiving antiretroviral therapy, ART. Problems of
drug failure related to drug resistance as a consequence of
individual pharmacogenetics and adherence problems rendering
drug levels suboptimal remains a major obstacle for clinicians to
choose an effective antiretroviral regime. Once resistant strains of
HIV are selected in the host population, they can be transmitted to
new hosts and spread in the population at risk. Resistance-
associated mutations of HIV have been documented for each of
the different classes of antiretroviral drugs [1,2,3]. After a
continuous increase of transmitted drug resistance (TDR) over
several years in Western Europe stable or decreasing trends of
TDR were reported [4,5,6,7,8].
Studies of the impact of primary resistance on treatment
response [9,10] are limited by the fact that many have been
undertaken before routine baseline resistance testing became
common, and therefore inactive drugs were often utilised, and
associated with either reduced treatment response, or no effect.
Data on the impact of genotypic resistance testing on the
composition of first-line therapy are scarce [11,12,13]. Some
studies indicate variation among treatment strategies of physicians.
Differences in HIV treatment practices have been attributed not
only to medical factors but also to non-medical factors such as
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investigate the prevalence of TDR and the impact of the infection
with resistant HIV on treatment success in patients with a known
or well estimated date of seroconversion as best approximation for
the date of infection in the German HIV-1 Seroconverter cohort.
Methods
Study population
The study was approved by the local ethical committee of the
Charite ´, University Medicine, Berlin, Germany. Written informed
consent was given by all patients. The HIV-1 Seroconverter Study
is a nationwide multicentre observational study based on an open
cohort of HIV-1-infected persons for whom the date of
seroconversion is known (1. acute seroconverters) or can be
estimated (2. documented seroconverters).
1. Acute seroconverters: laboratory diagnostic criteria for an
acute seroconversion were i) detectable HIV-1 RNA (or p24
antigen) combined with a negative or indeterminate ELISA
result or ii) reactive HIV-1-ELISA combined with a negative or
indeterminate immunoblot-result followed by confirmation of
complete seroconversion within 6 months. In persons recruited
during seroconversion the date of the first reactive test was used
as an approximation for the infection date.
2. Documented seroconverters: individuals with a last negative
and a first positive HIV-antibody test with a maximum three
year interval were recruited for the study. In documented
seroconverters the mid-point between the dates of the last
negative and the first positive HIV-antibody test was used to
estimate the time of infection.
As we performed a long term observational study, various
commercial kits to determine viral load (VL) with different
detection limits were used over time. In this analysis viral
suppression was determined as treatment success in case of
viraemic suppression to at least 500 copies/ml including any
category of low-level viral load measurement (,400, ,50 and
,40 copies/ml). Two consecutive viral load measurements within
5 to 12 months after initiation of first line therapy were mandatory
for inclusion into the analysis of treatment success. Two or more
consecutive viral load measurements ,500 copies/ml were
categorised as virological failure. We defined 3 months as a
minimum duration of first line treatment to analyse for treatment
success.
Genotypic resistance testing
At enrolment baseline blood samples were collected from each
individual. Genotypic resistance testing was only performed for
antiretroviral-naı ¨ve patients. The ViroSeq
TM HIV-1 Genotyping
System was applied according to the instructions of the
manufacturer (Abbott, Germany). Alternatively, viral RNA was
extracted from plasma using the viral RNA Kit (Qiagen,
Germany) and reverse transcribed (70 ml plasma equivalents) with
Superscript II (Invitrogen, Germany) and amplified with the
Expand high fidelity PCR system (Boehringer, Germany). The
1.5-kb pol fragments encoding the complete protease (99 amino
acids) and reverse transcriptase (1–296 amino acids) were directly
sequenced using in-house primers. This method has already been
described elsewhere [12,17]. For the purpose of this study, the
surveillance drug resistance mutations list (Bennett D, Camacho
R, Otela D, Kuritzkes D, Fleury H et al., 2009) was used for
identification of resistance associated-mutations [18,19] and the
prevalence of TDR. TDR was considered if any of these mutations
was present and the prevalence of TDR was calculated by year of
seroconversion.
Statistical analyses
Proportions were calculated with a 95% Wilson score confidence
interval based on a binomial distribution. Median values were given
with the interquartile ranges (IQR). –Due to low numbers Fishers’s
exacttest wasused to compare proportions.The Mann-Whitney-U-
test (MWT) was used to compare age, viral loads and CD4-cell-
counts. Trends in the prevalence of TDR were calculated by logistic
regressionequivalent to the Cox-Armitagetrend test. Kaplan-Meier
analysis was used for the comparison of duration of first line
regimen. Two consecutive viral load measurements within 5 to 12
months after initiation of first line therapy were mandatory for
inclusion into the analysis of treatment success. Two or more
consecutive viral load measurements above 500 copies/ml were
categorised asvirological failure. Therapeutic successwasdefinedas
viral suppression below the detection limit of at least #500 copies/
ml. We defined 3 months as a minimum duration of first line
treatment. All p-values are two sided, and a p-value of ,0.05 was
considered significant. All data were analysed using SPSS 17.0.
Results
Population characteristics
Of 1,564 HIV-positive patients with a known or estimated date
of seroconversion 1,312 primary samples from drug-naı ¨ve patients
were available and included into the analysis. All study
participants seroconverted between 01.01.1996 and 31.12.2007.
Genotyping was performed in 1,276/1,312 available samples of
treatment naive patients (97.3%). There was no bias between the
seroconverters genotyped and the group of patients not included
(no sample available or already treated at study entry with respect
to exposure categories etc (data not shown). Nearly two thirds of
patients were documented seroconverters (845/1,276; 66.2%;
table 1). 33.8% were acute seroconverters (431/1,267) defined by
laboratory criteria. 95.0% of the patients were male (1,212/1,267),
64 patients were female. In Germany data about route of
transmission in HIV cases reported through the routine national
surveillance system were documented in 85% of all patients newly
diagnosed with HIV-1 infection (date of infection not known).
65%wereMSM,17%wereheterosexuals,12%ofthe individuals
originated from high prevalence countries. Intravenous drug use
was reported for 5% of all reported HIV cases in 2008
(Epidemiological Bulletin, May 2009, Robert Koch-Institute,
Berlin, Germany). Concordantly with all reported HIV-1 cases in
Germany, the predominant route of transmission in the German
HIV-1 Seroconverter cohort was sex between men, MSM (85.2%).
Hence, our study has a bias towards MSM comparing to the
national HIV surveillance data. However, the proportion of the
transmission route is comparable to the national surveillance data.
NonB subtype was observed in 7.4% of the study participants.
CD4 cell counts/ml and plasma viral load measured at time of
seroconversion were 510 cells/ml (median; IQR: 380–652) and
5.17 log10/ml (median; IQR: 4.41–5.88), respectively (table 1).
Antiretroviral therapy was initiated in 34.7% (443/1,267) of
seroconverters. The median duration of the first-line regimen was
180 days (IQR 49–411).
Most patients who used their first-line regimen less than 49 days
changed substances within one day (57.8%; 63/109). Changes
within drug classes appeared in 39.7% of these patients (25/63).
Unfortunately, reasons for regimen switches were not systemati-
cally documented by the practitioners. However, 24 of these 63
patients with a prescribed 2NRTI/1NNRTI regimen and 23 of 63
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class. 30.3% (n=33) of the 109 patients dropped out and no
further information was available. The first-line regimen was
censored by the date of data extraction for this manuscript in 11
cases (10.1%). For the remaining 1.8% (n=2) no further treatment
information was available.
Genotypic resistance analysis
Prevalence and epidemiological trends in transmission of
drug resistance. Primary mutations according to the SDRM
list of Bennett et al. [18,20,21] were identified in 158/1,276
(12.4%) of viral strains. Overall, the prevalence of transmitted
drug resistance remained rather stable at 12.4% (CIWilson: 10.7–
14.3) during the period of observation (p for trend over time 1996–2007=
0.25) (figure 1). NRTI associated resistance (single class resistance)
was identified most frequently (6.3%; 80/1276; CIWilson: 5.0–7.8).
Followed by 2.4% NNRTI resistance (30/1276; CIWilson: 1.6–3.4)
and 2.1% PI resistance (27/1276; CIWilson: 1.4–3.1). Dual- and
multi-class resistance was only seen in 1.4% and 0.2% of patients
with TDR, respectively. NRTI resistance reached a mean
prevalence of 7.5% (CIWilson: 6.2–9.1), if the numbers were
cumulated from all categories of transmitted resistance classes,
e.g. mono-, dual- and multi-resistant HIV (NNRTI resistance
3.5% CIWilson: 2.6–4.6; PI resistance 2.9% CIWilson: 2.1–4.0).
Prevalence of transmitted NRTI resistance dropped between 1999
and 2000 resulting in an overall declining trend (NRTI:
p for trend over time 1996–2007 =0.02) (fig. 2). In contrast, prevalence
Table 1. Characteristics of patients.
Total resistant HIV
a susceptible HIV OR (95%CI
#) p-Value
Drug-naive patients, first sample available, no. (%) 1276 158 (12.4) 1118 (87.6)
Median age at sc
& [years] (IQR
1) 33 (28.0–38.0) 33.5 (27.8–38.3) 33.0 (28.0–38.0) - 0.7
p
Sex, no. (%)
men 1212 (95.0) 151 (95.6) 1061 (94.9) 1.15 (0.52–2.59) 0.85
n
women 64 (5.0) 7 (4.4) 57 (5.1)
Exposure category, no. (%)MSM 1119 (87.7) 140 (88.6) 979 (87.6) 1.1 (0.66–1.86) 0.80
n
Heterosexual contacts 78 (6.1) 8 (5.1) 70 (6.3) 0.80 (0.38–1.69) 0.72
n
2.0) 1 (0.6) 25 (2.2) 0.28 (0.04–2.07) 0.24
n
IVD 21 (1.7) 1 (0.6) 20 (1.8) 0.35 (0.05–2.62) 0.50
n
unknown 32 (2.5) 8 (5.1) 24 (2.1) 2.43 (1.07–5.51) 0.05*
n
pol-subtype B, no. (%) 1182 (92.6) 154 (97.5) 1028 (91.9) 3.06 (1.16–8.08) 0.009**
n
pol-subtype non-B, no. (%) 94 (7.4) 4 (2.5) 90 (8.1)
Median viral load at sc [log10/ml] (IQR) 5.17 (4.4–5.9) 5.05 (4.4–5.6) 5.21 (4.4–5.9) - 0.56
p
Median CD4
+ cell count at sc [n/ml] (IQR) 518.5 (384.3–668.5) 555.0 (407.5–734.0) 515 (379.0–663.0) - 0.35
p
Median duration of first-line regimen[days] (IQR) 180.0 (49.0–411.0) 144.0 (48.0–365.5) 182.0 (49.0–431.8) - 0.56
p
Documented seroconversion, no. (%) 845 (66.2) 103 (65.2) 742 (66.7)
Median viral load at sc [log10/ml] (IQR) 4.81 (3.9–5.5) 4.71 (4.4–5.0) 4.86 (3.9–5.5) - 0.89
p
Median CD4
+ cell count at sc [n/ml] (IQR) 545.0 (401.0–732.5) 537.5 (390.3–778.5) 545.0 (395.0–732.0) - 0.97
p
Acute seroconversion, no. (%) 431 (33.8) 55 (34.8) 376 (33.6)
Median viral load at sc [log10/ml] (IQR) 5.32 (4.6–5.9) 5.14 (4.4–5.7) 5.35 (4.6–5.9) - 0.26
p
Median CD4
+ cell count at sc [n/ml] (IQR) 509.0 (373.0–651.0) 555.0 (407.0–726.0) 504.5 (364.0–646.0) - 0.22
p
aTDR according to Bennett et al., 2009,
&sc: seroconversion,
#CI: 95% confidence intervals,
1IQR: interquartile ranges;
*statistically significant results (p,0.05);
**highly statistically significant results (p,0.01);
pMann-Whitney - U Test;
nFisher exact test.
doi:10.1371/journal.pone.0012718.t001
Figure 1. Overall prevalence of TDR in the German HIV-1
Seroconverter Cohort 1997–2007. The prevalence of TDR (%) is
plotted by year of seroconversion (Bennett et al. 2009; 12.4%; CI 10.4–
14.3; p for trend=0.25. Numbers of genotyped HIV-infections were
indicated in brackets before the year of seroconversion.
doi:10.1371/journal.pone.0012718.g001
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Overall PI resistance remained stable among the study population
genotyped over the time (p for trend=0.24; figure 2).
Factors associated with transmitted drug resis-
tance. The prevalence of TDR was highest among patients
exposed to HIV-1 through sex between men (12.5%, CI: 10.7–
14.9; heterosexuals 10.3%; CI: 5.3–19.0; HPL 3.9%; CI: 0.7–18.9;
and IVDU 4.8%; CI: 0.9–22.7). Men acquired TDR more
frequently than women (12.5%, CI: 10.7–14.4; vs. 10.9%, CI: 5.4–
20.9), respectively. The median age at seroconversion did not
differ between patients with or without TDR (33.5; IQR 27.8–
38.3 vs. 33.0; IQR 28.0–38.0; pMWT =0.7) (table 1). In a
univariate analysis, there was no evidence to suggest, that TDR
was associated with sex (OR =1.15; CI: 0.5–2.6; pFisher Exact=
0.9). Being infected with subtype B virus was associated with a
significantly higher risk to acquire resistant HIV strains
(OR=3.06; CI: 1.16–8.08; pFisher Exact =0.009) and the
exposure category unknown is significantly more frequently
reported in patients with resistant HIV strains (OR=2.43; CI:
1.07–5.51; pFisher Exact =0.05; table 1).
Transmitted drug resistance is frequently caused by
single resistance mutations. TDR was mostly related to
viruses carrying single resistance mutations (figure S4). The
majority of NNRTI resistance, 99.1% was caused by a singleton
resistance mutation, followed by 68.4% singleton PI resistance
mutations and 55.6% singleton NRTI resistance mutations. TAM
mediated NRTI resistance was due in 54.4% to more than one
TAM present in the same viral genome.
Dominance of NRTI resistance mutations, TAMs and
T215 revertant substitutions. The majority of the NRTI
resistant strains (79.8%) carried thymidine analogue resistance
mutations (TAMs) selected by zidovudine and stavudine. Among
the TAMs, revertant amino acid substitutions at position 215 of
the reverse transcriptase were most prevalent (74.7%). Despite the
significant decrease of transmitted NRTI resistance there is no
clear cut decrease of either the prevalence of TAMs or the T215
revertant substitions (figure S1). T215 revertant substitutions were
by far the most prevalent resistance mutations (3.8%) in the study
population (figure 3).
Composition of antiretroviral first-line treatment in
patients with susceptible and resistant HIV
Analysis of treatment and treatment response was performed on
the basis of resistance data according to the SDRM list of
mutations. First-line therapy was initiated in 382/1,118 (34.2%)
patients with susceptible strains and in 61/158 (38.6%) patients
with TDR associated mutations.
First-line therapy of patients with susceptible
genotype. First-line therapy was initiated in 382 patients with
susceptible HIV strains and lasted for 182.0 days (median, IQR:
49.0–431.8). A Kaplan-Meier analysis revealed no significant
difference in duration of first-line therapy comparing susceptible
and resistant strains (x
2
Log Rank =0.004; p=0.95). Time between
seroconversion and ART initiation was 327 days (median, IQR,
66.8–652.5) and Kaplan-Meier showed no significant difference in
comparison to patients with resistant HIV strains (x
2
Log Rank =
0.454; p=0.50). CD4 cell count measurements reported at the
start of therapy were 335 cells/ml (median, IQR: 215.0–511.5) and
plasma HIV-RNA measurement of 5.3 log10/ml (median, IQR:
4.7–5.8). Any PI containing first line therapy was prescribed in
60.5% (231/382) of the patients with susceptible genotype.
Predominantly, a 2 NRTI/1 PIr regimen was used as first-line
therapy in 45.3% (173/382) of the patients. 34.3% (131/382) of
individuals with susceptible strains received a NRTI/NNRTI first-
line therapy. Any NNRTI comprising first-line therapy was
initiated in 38.7% (148/382) of the patients. Efavirenz was
preferred to nevirapine (92/148; 62.2% vs. 55/148; 37.2%,
respectively).
Figure 2. Proportion of TDR in the drug classes NRTI, NNRTI
and PI by year of seroconversion. Resistance to individual drug
classes was summed up for strains with single, dual- and multi-drug
resistance to calculate the prevalence of HIV resistance to the three
different drug classes. NRTI resistance decreased significantly over time
(p for trend =0.02). NNRTI resistance increased over time (p for trend =
0.07). PI resistance remained stable over time (p for trend =0.24). The
cumulated numbers which where used to calculate the prevalence of
each of the drug classes is indicated in brackets together with the year
of seroconversion in the lowest panel of the figure (PI).
doi:10.1371/journal.pone.0012718.g002
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type. First line therapy was initiated in 61 patients (61/158)
with TDR. Time between seroconversion and start of first-line
therapy was 448 days (median, IQR 162–660). The durability of
the first-line regimen in this group was 144 days (median, IQR:
48–365). CD4 cell counts measured at time of antiretroviral
treatment initiation were 312 cells/ml median and did not differ
significantly to the susceptible group (IQR: 200–458; pMWT=
0.48). Also, plasma viral load was not significantly lower in patients
with resistant strains compared to initial viral load measurements
in the susceptible group (median, log10/ml: 5.2; IQR: 4.6–5.5;
pMWT=0.36). Comparing VL between acute seroconverters with
and without TDR, no significant difference was observed. First-
line regimen containing any PI were used in 37/61 (60.7%)
patients with resistant HIV. Any NNRTI was used in 24/61
(39.3%) patients in the TDR group. Efavirenz was again the
preferred NNRTI compared to nevirapine in patients with TDR
(16/24; 66.7% vs. 6/24; 25.0%).
Treatment success in patients with susceptible and
resistant HIV
Viral suppression in patients with susceptible
phenotype. Data about any viral load measurement during
first year of first-line therapy were available for 271/382 (71%) of
the patients with susceptible genotype. After applying the
minimum duration of first-line therapy, e.g. 3 months, the
patients included were 184/252 (73%). Consecutive viral load
measurements within 5 to 12 months after treatment initiation
were scarce. Data eligible for the analysis of treatment success
were available only from 37.5% (69/184) of antiretroviral treated
patients in the cohort. The majority of these patients with
available viral load data (89.9%, 62/69) were treated successfully.
Only 2.9% (2/69) of individuals did not reach the viral load limit
(#500 copies/ml) between 5–12 months after start of therapy. 5/
69 (7.2%) patients were reported to have had two to three
detectable viral load measurements after viraemic suppression
(table 2).
Viral suppression in patients with resistant
phenotype. Data about any viral load measurement data
during first year of first-line therapy – taking the minimum
duration of first line therapy into account - were available for 9/40
(22.5%) of patients with resistant HIV (table 2). Therapeutic
success was achieved in the majority of treated patients (7/9,
77.8%). Two patients did not reach viraemic suppression (#500
copies/ml) between 5–12 months after start of therapy.
Time trend in treatment response in patients with
susceptible phenotype. Referring to the subpopulation
entered into the analysis of treatment success, we performed an
analysis on time trends in response to therapy solely in the group
of patients infected with susceptible HIV strains (69 patients). We
excluded the group of patients infected with resistant HIV due to
small numbers (9 patients were entered into analysis on treatment
success).
We used a logistic regression equivalent to the Cox-Armitage
trend test. In this logistic regression analysis we applied as
dependent variable binary coded treatment success and as
covariant ‘Year of start of first line therapy’ (categories were:
1997–2000=0; 2001–2004=1; 2005–2007=2). The result indi-
cates that with the higher the category the more likely to have
treatment success (b=0.32; p=0.12; OR=1.37; CI: 0.93–2.04).
However note, that the result is not significant at the alpha=0.05
level.
Discussion
In contrast to trends of TDR reported in other European
cohorts [4,6,22,23,24,25,26], prevalence of TDR was stable at a
high level during a decade of observation (1997–2007) in the
German HIV-1 Seroconverter cohort [18,19]. Estimates of the
prevalence of TDR may vary in cohorts because of differences in
the study design, geographical location, definitions and classifica-
tions of TDR and composition of the study population. Prevalence
of resistance is higher in patients with a known date of infection
than in patients with an established but unknown date of HIV-
infection. This was supported by lower prevalence of TDR in
Figure 3. Prevalence of resistance mutations identified between 1997 and 2007. HIV resistance mutations (SDRM list) which occurred at a
prevalence of $0.7% in treatment naı ¨ve seroconverters were depicted. The RT mutations K65R, T69i, L74VI, V75AMTS, F116Y, Q151M, K219R; L100I,
K101EP, P225H and the PR mutation L23I; I50VL, L76V never occurred. Bars in light grey: TAMS; Bars in dark grey: NRTI resistance mutations, black
bars: NNRTI resistance mutations, white bars: PI resistance mutations.
doi:10.1371/journal.pone.0012718.g003
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multi centre cohort in the state of Nordrhine-Westfalia in
Germany (9%; 95% CI 7.1–10.9) [27]. Reversion to wild type of
resistance mutations affecting viral fitness from the dominant
quasispecies over time is supposed to be the reason for the lower
prevalence of TDR in chronically infected patients. As an example
the mutations M184V and T215Y/F known to strongly reduce
viral replication efficiency were never observed in chronically
infected patients [30] in contrast to the population of newly
infected HIV-1 seroconverters analysed in this study (M184V
n=10 and T215YF n=10, espectively; figure 3).
The significant decrease of NRTI-related resistance over time
(p=0.02) in this population might have been caused by several
factors. The reduction of the intensive use of mono- and dual
therapies in previous years and the reduced replication capacity of
viruses harbouring NRTI and multi drug resistance are associated
with the reduced prevalence of NRTI resistance [28,29].
Additionally, improved treatment strategies, low tolerance of
detectable viral load, and prompt management of treatment
failure by the physicians might have lead to a reduction of NRTI
resistance in treatment experienced persons subsequently influ-
encing the spread of TDR in patients recently infected with HIV.
Indeed, the decrease of NRTI resistance coincided with a decrease
of the prevalence of the lamivudine selected mutation M184V and
the TAMs T215YF, K219Q, K70R, in patients newly infected
with HIV (figure S2). In contrast, some distinct NNRTI mutations
(P225H, G190AS and Y181C) and also HIV strains carrying more
than one NNRTI mutation were only observed since 2003/2004
and might contribute to the increase in NNRTI-resistance (figure
S3), whereas the prevalence of the prominent NNRTI mutation
K103NS (2.3%) is stable during the observation period (figure S3).
The overall prevalence of viruses with genotypic resistance in
recently HIV-infected individuals did not vary over time [30],
although the distribution of resistance between individual drug
classes has changed as also shown in our study. The most common
NRTI-resistance mutations detected in treatment-naı ¨ve patients
were M184V/I and TAMs, reflecting the extensive use of 3TC,
ZDV and d4T and the use of mono and dual NRTI-therapy in the
pre- and early HAART era. The T215 revertant was the most
prevalent NRTI related mutation among patients with primary
resistance [13,31]. These strains are phenotypically susceptible to
zidovudine and stavudine in vitro but are able to acquire T215Y
more rapidly than the wild type under the selective pressure of
zidovudine [32–33]. Evidence exists that T215 revertants replicate
as efficiently as the wild-type virus or even gained improved fitness
and growth advantage compared to T215Y/F [34,35,36].
Many treatment options are available for the initial antiretro-
viral regimen of patients infected with HIV [37,38]. Reports
describing the inferior treatment outcome in patients harbouring
TDR, were frequently published [2,22,39]. If resistance testing is
not possible or the patients needs to commence treatment before
resistance results are available in case of low CD4 numbers, it may
be advisable to initiate treatment with a boosted PI-regimen [40],
Taking into account that boosted PIs have a higher barrier to
develop resistance, an accumulation of mutations is required to
induce PI-related resistance. As observed in this cohort, the
majority of the patients either carrying susceptible or resistant HIV
strains, was treated with any PI comprising regimen as the first-line
regimen. Mostly, a ritonavir boosted lopinavir/NRTI first-line
regimen was preferred, reflecting the extended therapeutic options
since PIs of the second generation were available for treatment.
It was previously assumed, that TDR detected at HIV-diagnosis
would not impact the course of infection as fitter wild-type strains
would become the dominant quasispecies. It is now well known,
that TDR can persist for years as dominant quasispecies [41] and
for even longer in a minority of the viral quasispecies in plasma
(RNA) and as archived resistance within proviral DNA copies in
the genome of peripheral blood mononuclear cells (PBMCs) [34]
and other target cells of HIV. Therefore treatment response might
be influenced by TDR even after many years, resulting in ongoing
viral replication under selective pressure and promoting the
evolution of further resistant variants [42]. First results in this study
showed that treatment response was successful in patients with
TDR bearing in mind that only small numbers of viral load
measurements after start of therapy were available [10].
More than half of the patients in both groups (resistant 77.8%;
susceptible 89.9%) were reported to be under detection limit
within 5–12 months (#500 copies/ml) after start of antiretroviral
treatment. A long-term observation of the changes in the
composition of individual antiretroviral regimen and monitoring
of the treatment outcome is necessary to assess treatment success
adequately. As reported in other studies, the presence of
revertants, which were identified at a high prevalence in this
study, seems to have a negative impact on virological response
[6,35,43]. However, the results of this study underline the fact that
most persons with TDR have good treatment outcome by using
resistance testing to guide the choice of a first-line regimen [13,44].
Our findings reinforce that a broad and representative HIV
resistance surveillance network between virologists, practitioners,
clinicians and patients has to be installed to intensify the
epidemiological knowledge about the transmission of resistant
HIV, genotypic resistance testing frequencies, and treatment
response in patients carrying resistant strain.
Supporting Information
Figure S1 Prevalence of TAMs and NRTI resistance mutations
by year of seroconversion. The prevalences of TAMs and NRTI
resistance mutations (SDRM list) were calculated by year of
seroconversion.
Found at: doi:10.1371/journal.pone.0012718.s001 (0.23 MB TIF)
Table 2. Treatment success of patients with susceptible and resistant HIV 5–12 months after ART- initiation.
Characteristics of patients on first line therapy (FLT) Predicted phenotype
Susceptible Resistant
Viral load (VL) data available within 12 months of FLT and .1 VL report 69/184 (37.5%) 9/40 (22.5%)
Failure: 2 or more VL .500 copies/ml 2/69 (2.9%) 2/9 (22.2%)
Success: VL constant #500 copies/ml 62/69 (89.9%) 7/9 (77.8%)
Any detectable viral load measurements: 1 VL .500 copies/ml 5/69 (7.2%) none
doi:10.1371/journal.pone.0012718.t002
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seroconversion. The prevalences of each of TAMs and other
NRTI resistance mutations (SDRM list) were calculated per year
of seroconversion. A TAMs. Never observed: K219R. B NRTI
resistance mutations other than TAMs. Never observed: K65R,
T69i, L74V, V75AMTS, F116Y, Q151M.
Found at: doi:10.1371/journal.pone.0012718.s002 (0.88 MB TIF)
Figure S3 Prevalence of NNRTI and PI resistance mutations by
year of seroconversion. The prevalences of each of the NNRTI
and PI resistance mutations (SDRM list) were calculated by year of
seroconversion. A NNRTI resistance mutations. Never observed:
L100I, K101E, V106M, Y181I, G190EQ, M230L (P236L not
included). B PI resistance mutations. Occurred once: L24I, V32I,
G48V, G73ACST.
Found at: doi:10.1371/journal.pone.0012718.s003 (0.73 MB TIF)
Figure S4 Prevalence of TDR caused by one or more resistance
mutations in the HIV genome by year of seroconversion.
Found at: doi:10.1371/journal.pone.0012718.s004 (0.51 MB TIF)
Acknowledgments
The authors thank Sabrina Neumann, Parvin Ghassim, Hanno von
Spreckelsen, Britta Klose, and Katrin Arndt and the sequencing service
team of the Robert Koch-Institute for their skilled technical and
administrative assistance and Christian Kollan and Bernd Reinhardt for
the development of the data base.
The authors thank also all the participating collaborators of the German
HIV-1 Seroconverter Study Group: Aachen: Dres. Habets and Knechten;
Augsburg: Dr. Hammond (Klinikum Augsburg); Berlin: Dres. Mayr,
Schmidt, Speidel, and Strohbach (Medizinisches Versorgungszentrum,
A ¨rzteforum Seestrabe), PD Dr. Araste ´h (Auguste-Viktoria-Krankenhaus/
Vivantes), Dres. Bieniek and Cordes, Dr. Claus, Dres. Baumgarten,
Carganico, and Dupke, Dres. Freiwald and Rausch, Dres. Go ¨lz, Klausen,
Moll, and Schleehauf, Dr. Hintsche, Dres. Jessen and Jessen, Dres. Ko ¨ppe
and Krauthausen, Dr. Reuter; Bielefeld: Dr. Pfaff (Krankenhaus MARA
II); Bochum: Prof. Dr. Brockmeyer (St. Joseph-Hospital); Bonn: Prof. Dr.
Rockstroh (Universita ¨tsklinik Bonn); Dortmund: Prof. Dr. Gehring and Dr.
Schmalo ¨er and Dr. Hower (Klinikum Dortmund, ID27 Ambulanz);
Dresden: Prof. Dr. Spornraft-Ragaller (Universita ¨tsklinikum Dresden);
Duisburg: Dr. Becker-Boost, Dr. Kwirant; Du ¨sseldorf: Prof. Dr. Ha ¨us-
singer and PD Dr. Reuter (Universita ¨tsklinik Du ¨sseldorf); Frankfurt/Main:
Prof. Dr. Helm (Universita ¨tsklinik Johann-Wolfgang-Goethe-Universita ¨t);
Frankfurt/Oder: Dr. Markus; Halle/Saale: Dr. Kreft (Universita ¨tsklinik
Martin-Luther-Universita ¨t); Hamburg: Prof. Dr. Plettenberg, Dr. Stoehr,
Dr. Graefe, and Dr. Lorenzen (Institut fu ¨r Infektionsmedizin, ifi,
Allgemeines Krankenhaus St. Georg); Dres. Adam, Schewe, and Weitner,
Dr. Fenske, Dr.Hansen, Prof. Dr. Stellbrink (Infektionsmedizinisches
Zentrum Hamburg, ICH); Hannover: Prof. Dr. Schmidt (Medizinische
Hochschule Hannover), Dres. Buck and Leugner; Koblenz: Prof. Dr.
Eisenhauer and Dr. Rieke (Krankenhaus Kemperhof); Ko ¨ln: Dr. Bihari,
Dr. Ferdinand, Prof. Dr. Fa ¨tkenheuer (Universita ¨tsklinik Ko ¨ln); Prof. Dr.
Oette, Krankenhaus der Augustinerinnen, Ko ¨ln; Leipzig: Dr. Pfeil
(Universita ¨tsklinik Leipzig); Magdeburg: Prof. Dr. Malfertheiner and Dr.
Wolle (Universita ¨tsklinik Otto-v.-Guericke-Universita ¨t); Mainz: Prof. Dr.
Galle (Klinikum der Joh.-Gutenberg-Universita ¨t); Mu ¨nchen: Dres. Ja ¨ger
and Ja ¨gel-Guedes, Dr. Malm, Dr. Rieger, Sta ¨dtisches Krankenhaus
Mu ¨nchen-Schwabing, Prof. Dr. Fro ¨schl (Technische Universita ¨t
Mu ¨nchen); Mu ¨nster: Prof. Dr. Rahn, (Universita ¨tsklinik Mu ¨nster);
Norderstedt: Dr. Soldan; Nu ¨rnberg: Dr. Brockhaus (Klinikum Nu ¨rnberg);
Osnabru ¨ck: Dr. Mutz (Sta ¨dtische Klinik Natruper Holz); Regensburg:
Prof. Dr. Salzberger, Prof. Dr. Scho ¨lmerich, and Dr. Schneidewind
(Universita ¨tsklinik Regensburg); Remscheid: Dr. Steege; Rostock: Dr.
Kreft, Prof. Dr. Ziegler and Prof. Dr. Reisinger (Universita ¨tsklinik
Rostock); Stuttgart: Dres. Ibler, Schaffert, Schnaitmann, and Trein, Dres.
Frietsch, Mu ¨ller, and Ulmer; Dr. Wagner-Wiening (Landesgesundheitsamt
Stuttgart); Ulm: Prof. Dr. Kern and Prof. Dr. Dr. Kreidler (Universi-
ta ¨tsklinik Ulm); Viernheim: Dr. van Treek; Wiesbaden: Dr. Starke.
Author Contributions
Conceived and designed the experiments: BB CK OH. Performed the
experiments: KK SS. Analyzed the data: CH JW CK. Contributed
reagents/materials/analysis tools: HJ SD. Wrote the paper: BB.
References
1. Fauci AS (1995) HIV. An elusive soluble suppressor. Nature 378: 561.
2. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-
drug resistance among patients recently infected with HIV. N Engl J Med 347:
385–394.
3. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2007)
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15: 119–125.
4. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, et al. (2008)
The incidence of multidrug and full class resistance in HIV-1 infected patients is
decreasing over time (2001-2006) in Portugal. Retrovirology 5: 12.
5. de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I,
et al. (2007) Changing rates and patterns of drug resistance mutations in
antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses
23: 879–885.
6. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, et al. (2007)
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular
epidemiology survey. Aids 21: 2223–2229.
7. SPREAD programme (2008) Transmission of drug-resistant HIV-1 in Europe
remains limited to single classes. Aids 22: 625–635.
8. Vercauteren J, Wensing AM, van de Vijver DA, et al. (2009) , Albert J (2009)
Transmission of drug resistant HIV is stbilizing in Europe. Journal of Infectious
Disease.
9. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time
trends in primary HIV-1 drug resistance among recently infected persons. Jama
288: 181–188.
10. Little SJ, Smith DM (2005) HIV treatment decisions and transmitted drug
resistance. Clin Infect Dis 41: 233–235.
11. Tozzi V, Bellagamba R, Castiglione F, Amendola A, Ivanovic J, et al. (2008)
Plasma HIV RNA decline and emergence of drug resistance mutations among
patients with multiple virologic failures receiving resistance testing-guided
HAART. AIDS Res Hum Retroviruses 24: 787–796.
12. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, et al. (2001) Frequency
of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients
of the German Seroconverter Study. J Acquir Immune Defic Syndr 26: 266–273.
13. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, et al. (2006) Primary
HIV drug resistance and efficacy of first-line antiretroviral therapy guided by
resistance testing. J Acquir Immune Defic Syndr 41: 573–581.
14. Bogart LM, Kelly JA, Catz SL, Sosman JM (2000) Impact of medical and
nonmedical factors on physician decision making for HIV/AIDS antiretroviral
treatment. J Acquir Immune Defic Syndr 23: 396–404.
15. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, et al. (2008) Durability
and Outcome of Initial Antiretroviral Treatments Received during 2000-
2005 by Patients in the Swiss HIV Cohort Study. J Infect Dis 197: 1685–
1694.
16. Parruti G, Manzoli L, Toro PM, D’Amico G, Rotolo S, et al. (2006) Long-term
adherence to first-line highly active antiretroviral therapy in a hospital-based
cohort: predictors and impact on virologic response and relapse. AIDS Patient
Care STDS 20: 48–56.
17. Poggensee G, Kuecherer C, Werning J, Somogyi S, Bieniek B, et al. (2007)
Impact of transmission of drug-resistant HIV on the course of infection and the
treatment success. Data from the German HIV-1 Seroconverter Study. HIV
Med 8: 511–519.
18. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1
protease and reverse transcriptase mutations for drug resistance surveillance.
Aids 21: 215–223.
19. Shafer RW, Rhee SY, Bennett DE (2008) Consensus drug resistance mutations
for epidemiological surveillance: basic principles and potential controversies.
Antivir Ther 13 Suppl 2: 59–68.
20. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug
resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009
update. PLoS One 4: e4724.
21. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated
framework for the second decade of HAART. AIDS Rev 10: 67–84.
22. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:
implications for clinical management. J Infect Dis 192: 958–966.
23. Geretti AM (2006) Clinical implications of HIV drug resistance to nucleoside
and nucleotide reverse transcriptase inhibitors. AIDS Rev 8: 210–220.
24. de Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V (2002) Decline
in the rate of genotypic resistance to antiretroviral drugs in recent HIV
seroconverters in Madrid. Aids 16: 1830–1832.
25. (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United
Kingdom. Aids 21: 1035–1039.
Transmitted Drug Resistance
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e1271826. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, et al. (2004)
Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Aids 18:
1571–1577.
27. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, et al. (2007) Trends of
prevalence of primary HIV drug resistance in Germany. J Antimicrob
Chemother 60: 843–848.
28. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, et al. (2004) Diminished
representation of HIV-1 variants containing select drug resistance-conferring
mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 37:
1627–1631.
29. Brenner BG, Turner D, Wainberg MA (2002) HIV-1 drug resistance: can we
overcome? Expert Opin Biol Ther 2: 751–761.
30. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, et al. (2002)
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected
individuals. Aids 16: 1511–1519.
31. Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al. (2007)
[Epidemiology of primary drug resistance in chronically HIV-infected patients in
Nordrhein-Westfalen, Germany, 2001–2005]. Dtsch Med Wochenschr 132:
977–982.
32. Cuevas MT, Munoz-Nieto M, Thomson MM, Delgado E, Iribarren JA, et al.
(2009) HIV-1 Transmission Cluster With T215D Revertant Mutation Among
Newly Diagnosed Patients From the Basque Country, Spain. J Acquir Immune
Defic Syndr.
33. Geretti AM (2007) Epidemiology of antiretroviral drug resistance in drug-naive
persons. Curr Opin Infect Dis 20: 22–32.
34. Pao D, Andrady U, Clarke J, Dean G, Drake S, et al. (2004) Long-term
persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir
Immune Defic Syndr 37: 1570–1573.
35. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D’Elia S, et al. (2004) Risk of
failure in patients with 215 HIV-1 revertants starting their first thymidine
analog-containing highly active antiretroviral therapy. Aids 18: 227–235.
36. Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W (2004)
Transmitted human immunodeficiency virus type 1 carrying the D67N or
K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a
high replicative fitness in the presence of zidovudine. J Virol 78: 7545–7552.
37. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, et al. (2008)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recom-
mendations of an International AIDS Society-USA panel. Clin Infect Dis 47:
266–285.
38. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al.
(2008) Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top
HIV Med 16: 62–68.
39. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008)
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med
358: 2095–2106.
40. Waters L, John L, Nelson M (2007) Non-nucleoside reverse transcriptase
inhibitors: a review. Int J Clin Pract 61: 105–118.
41. Neifer S, Somogyi S, Schlote F, Berg T, Poggensee G, et al. (2006) Persistence of
a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33
months in the absence of treatment. Aids 20: 2231–2233.
42. Booth CL, Geretti AM (2007) Prevalence and determinants of transmitted
antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59:
1047–1056.
43. Garcia-Lerma JG (2005) Diversity of thymidine analogue resistance genotypes
among newly diagnosed HIV-1-infected persons. J Antimicrob Chemother 56:
265–269.
44. Shet A, Berry L, Mohri H, Mehandru S, Chung C, et al. (2006) Tracking the
prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of
experience. J Acquir Immune Defic Syndr 41: 439–446.
Transmitted Drug Resistance
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e12718